TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-controlled Parallel Group, Phase II Dose-Ranging Study of Nebulized Amikacin Delivered Via the Pulmonary Drug Delivery System (PDDS) in Ventilated Patients With Nosocomial Pneumonia Due to Gram Negative Organisms
Brief Summary: This study is part of a research program too see if amikacin delivered as an aerosol directly to the lungs in combination with IV antibiotic therapy can help intubated patients with gram-negative pneumonia get better faster than when given intravenous antibiotics alone. The primary purpose of this study is to determine the correct dose of amikacin which is delivered directly to the lungs as an aerosol via an investigational device called the Pulmonary Delivery Device System (PDDS).


Options:
A: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Amikacin (BAY41-6551) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Amikacin (BAY41-6551) | Arm Label: Arm 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Amikacin (BAY41-6551); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Amikacin (BAY41-6551); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Procalcitonin guided strategy | Intervention Type: PROCEDURE; Name: Procalcitonin guided strategy; Assigned to Arm(s): 1
D: Arm Label: Doripenem; Type: EXPERIMENTAL; Interventions: Drug: Doripenem, Drug: Placebo | Arm Label: Imipenem-Cilastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipenem-Cilastatin, Drug: Placebo | Intervention Type: DRUG; Name: Doripenem; Assigned to Arm(s): Doripenem | Intervention Type: DRUG; Name: Imipenem-Cilastatin; Assigned to Arm(s): Imipenem-Cilastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Doripenem, Imipenem-Cilastatin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between Low Carbohydrate Diet and Traditionally Recommended Diabetic Diet in the Treatment of Diabetes Mellitus Type 2.
Brief Summary: The purpose of the clinical trial is to investigate whether low carbohydrate diet is better than the traditional diabetic diet in the treatment of patients with diabetes mellitus type 2, for blood sugar and body weight.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2
B: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
C: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil
D: Arm Label: Insulin glargine + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: omega-3 polyunsaturated fatty acids (PUFA), Device: reusable pen device for insulin injection | Arm Label: Insulin glargine + placebo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: placebo, Device: reusable pen device for insulin injection | Arm Label: Standard care + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: omega-3 polyunsaturated fatty acids (PUFA) | Arm Label: Standard care + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: insulin glargine (HOE901); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo | Intervention Type: DRUG; Name: omega-3 polyunsaturated fatty acids (PUFA); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Standard care + omega-3 polyunsaturated fatty acids | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Insulin glargine + placebo, Standard care + placebo | Intervention Type: DEVICE; Name: reusable pen device for insulin injection; Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between Low Carbohydrate Diet and Traditionally Recommended Diabetic Diet in the Treatment of Diabetes Mellitus Type 2.
Brief Summary: The purpose of the clinical trial is to investigate whether low carbohydrate diet is better than the traditional diabetic diet in the treatment of patients with diabetes mellitus type 2, for blood sugar and body weight.


Options:
A: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
B: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Mediterranean diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Low-fat diet | Intervention Type: OTHER; Name: Mediterranean diet; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Low-fat diet; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between Low Carbohydrate Diet and Traditionally Recommended Diabetic Diet in the Treatment of Diabetes Mellitus Type 2.
Brief Summary: The purpose of the clinical trial is to investigate whether low carbohydrate diet is better than the traditional diabetic diet in the treatment of patients with diabetes mellitus type 2, for blood sugar and body weight.


Options:
A: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
B: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
C: Intervention Type: BEHAVIORAL; Name: Mono Unsaturated Fatty Acids in Obesity; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between Low Carbohydrate Diet and Traditionally Recommended Diabetic Diet in the Treatment of Diabetes Mellitus Type 2.
Brief Summary: The purpose of the clinical trial is to investigate whether low carbohydrate diet is better than the traditional diabetic diet in the treatment of patients with diabetes mellitus type 2, for blood sugar and body weight.


Options:
A: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
B: Intervention Type: OTHER; Name: Dietary fructose; Assigned to Arm(s): N/A
C: Arm Label: Sucrose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Sucrose | Arm Label: Aspartame; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Aspartame | Intervention Type: DIETARY_SUPPLEMENT; Name: Sucrose; Assigned to Arm(s): Sucrose | Intervention Type: DIETARY_SUPPLEMENT; Name: Aspartame; Assigned to Arm(s): Aspartame
D: Arm Label: CONTROL; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet | Arm Label: LOW SUG; Type: EXPERIMENTAL; Interventions: Other: Diet | Arm Label: LOW CHO; Type: EXPERIMENTAL; Interventions: Other: Diet | Intervention Type: OTHER; Name: Diet; Assigned to Arm(s): CONTROL, LOW CHO, LOW SUG

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between Low Carbohydrate Diet and Traditionally Recommended Diabetic Diet in the Treatment of Diabetes Mellitus Type 2.
Brief Summary: The purpose of the clinical trial is to investigate whether low carbohydrate diet is better than the traditional diabetic diet in the treatment of patients with diabetes mellitus type 2, for blood sugar and body weight.


Options:
A: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
B: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention
C: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Mono Unsaturated Fatty Acids in Obesity; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between Low Carbohydrate Diet and Traditionally Recommended Diabetic Diet in the Treatment of Diabetes Mellitus Type 2.
Brief Summary: The purpose of the clinical trial is to investigate whether low carbohydrate diet is better than the traditional diabetic diet in the treatment of patients with diabetes mellitus type 2, for blood sugar and body weight.


Options:
A: N/A
B: Arm Label: American Diabetes Association recommended diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: American Diabetes Association Diet | Arm Label: Low Carbohydrate Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Low Carbohydrate, Ketogenic Diet, Behavioral: Mindfulness and Positive Affect Skills | Intervention Type: BEHAVIORAL; Name: Behavioral: Low Carbohydrate, Ketogenic Diet; Assigned to Arm(s): Low Carbohydrate Diet | Intervention Type: BEHAVIORAL; Name: American Diabetes Association Diet; Assigned to Arm(s): American Diabetes Association recommended diet | Intervention Type: BEHAVIORAL; Name: Mindfulness and Positive Affect Skills; Assigned to Arm(s): Low Carbohydrate Diet
C: Arm Label: Low carbohydrate diet (F); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low carbohydrate - high fat diet | Arm Label: Traditional diet (K); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High carbohydrate - low fat diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low carbohydrate - high fat diet; Assigned to Arm(s): Low carbohydrate diet (F) | Intervention Type: DIETARY_SUPPLEMENT; Name: High carbohydrate - low fat diet; Assigned to Arm(s): Traditional diet (K)
D: Arm Label: 20% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 20% protein-diet | Arm Label: 27% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 27% protein-diet | Arm Label: 35% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 35% protein-diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 20% protein-diet; Assigned to Arm(s): 20% protein hypocaloric diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 27% protein-diet; Assigned to Arm(s): 27% protein hypocaloric diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 35% protein-diet; Assigned to Arm(s): 35% protein hypocaloric diet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study Comparing Two Different Sirolimus-based Transition Regimens in African-American Renal Transplant Recipients
Brief Summary: This study's focus is to compare the level effectiveness and safety of regimens involving Sirolimus, Cellcept and steroid to Prograf, Sirolimus and steroid in African-American recipients of kidney transplants.


Options:
A: Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclosporine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: daclizumab; Assigned to Arm(s): N/A
C: Arm Label: Tacrolimus Withdrawal Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: rapamune, mycophenolate mofetil and steroid | Arm Label: Tacrolimus Minimization Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus, sirolimus and steroid | Intervention Type: DRUG; Name: rapamune, mycophenolate mofetil and steroid; Assigned to Arm(s): Tacrolimus Withdrawal Arm | Intervention Type: DRUG; Name: tacrolimus, sirolimus and steroid; Assigned to Arm(s): Tacrolimus Minimization Arm
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AUC monitored withdrawal of MMF or CNI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: AUC monitored withdrawal of MMF or CNI | Intervention Type: DRUG; Name: AUC monitored withdrawal of MMF or CNI; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: LEVP2005-1/Part B: A Double-blind, Placebo-Controlled, Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) as Prophylactic Treatment to Prevent HAE Attacks
Brief Summary: The study objective was to determine the safety and efficacy of C1INH-nf for the prevention of acute HAE attacks.


Options:
A: Arm Label: BCX4161 300 mg three times daily; Type: EXPERIMENTAL; Interventions: Drug: BCX4161, Drug: Placebo | Arm Label: BCX4161 500 mg three times daily; Type: EXPERIMENTAL; Interventions: Drug: BCX4161 | Arm Label: Placebo three times daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCX4161; Assigned to Arm(s): BCX4161 300 mg three times daily, BCX4161 500 mg three times daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BCX4161 300 mg three times daily, Placebo three times daily
B: Arm Label: Participants with hereditary angioedema (HAE); Type: N/A; Interventions: N/A
C: Arm Label: C1INH-nf First, then Placebo; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf), Drug: Placebo (saline) | Arm Label: Placebo First, then C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf), Drug: Placebo (saline) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): C1INH-nf First, then Placebo, Placebo First, then C1INH-nf | Intervention Type: DRUG; Name: Placebo (saline); Assigned to Arm(s): C1INH-nf First, then Placebo, Placebo First, then C1INH-nf
D: Arm Label: C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (saline) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): C1INH-nf | Intervention Type: DRUG; Name: Placebo (saline); Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol, Drug: Fluticasone Propionate/Salmeterol Combination Product | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol Combination Product; Assigned to Arm(s): Arm 1
B: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): N/A
D: Arm Label: Glycopyrronium bromide; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glycopyrronium bromide; Assigned to Arm(s): Glycopyrronium bromide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Phase II Clinical Trial to Evaluate Efficacy and Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme Patients After Complete Surgical Resection With Fluorescence Microscope
Brief Summary: 1. Primary outcome measure:

   a.Evaluation of the treatment impact on progression-free survival.
2. Secondary outcome measures:

   1. Safety evaluation.

      * Direct effects attributable cell obtaining and administration.
      * Adverse events during treatment.
      * Neurological deterioration quantified using the NIH Stroke Scale.
      * Autoimmune phenomena.
   2. Evaluation of impact on other efficiency clinical parameters.

      * Overall survival.
      * Quality of life measured with EORTC questionnaire.
   3. Study of specific immune response and correlates with clinical outcome.

      * Delayed hypersensitivity.
      * Humoral response to autologous tumor cells/tumoral lysate.
      * Cellular response (proliferation, cytokine production, specific cytotoxicity).
   4. Cell line characterization and correlate the final product with clinical efficacy.

      * Phenotypic studies.


Options:
A: Arm Label: Vaccination; Type: EXPERIMENTAL; Interventions: Biological: autologous dendritic cells | Intervention Type: BIOLOGICAL; Name: autologous dendritic cells; Assigned to Arm(s): Vaccination
B: Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide
C: Arm Label: Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Radiotherapy of the partial brain. | Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: RADIATION; Name: Radiotherapy of the partial brain.; Assigned to Arm(s): Radiotherapy
D: Arm Label: NovoTTF-100A device in combination with Temozolomide; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A device | Arm Label: Temozolomide alone, as the best known standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Intervention Type: DEVICE; Name: NovoTTF-100A device; Assigned to Arm(s): NovoTTF-100A device in combination with Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide alone, as the best known standard of care

Answer: A